# Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in Patients With Junctional Epidermolysis Bullosa

> **NCT05111600** · PHASE2,PHASE3 · TERMINATED · sponsor: **Holostem s.r.l.** · enrollment: 2 (actual)

## Conditions studied

- Junctional Epidermolysis Bullosa Non-Herlitz Type

## Interventions

- **DRUG:** Transplantation

## Key facts

- **NCT ID:** NCT05111600
- **Lead sponsor:** Holostem s.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-15
- **Primary completion:** 2024-03-12
- **Final completion:** 2024-11-22
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Development program review and update due to Sponsor re-organization
- **Last updated:** 2025-02-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05111600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05111600, "Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in Patients With Junctional Epidermolysis Bullosa". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05111600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*